Donald L. Siegel

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Joseph A. Fraietta, Simon F. Lacey, Elena J. Orlando et al. · Nature Medicine · 2018 · 1.7K citations · Full text

T Cell Therapy, Cancer Immunosurveillance, Chronic Lymphocytic Leukemia +6

CRISPR-engineered T cells in patients with refractory cancer

Edward A. Stadtmauer, Joseph A. Fraietta, Megan M. Davis et al. · Science · 2020 · 1.4K citations · Full text

Decade-long leukaemia remissions with persistence of CD4+ CAR T cells

J. Joseph Melenhorst, Gregory M. Chen, Meng Wang et al. · Nature · 2022 · 851 citations · Full text

Hematological Malignancy, Decade-long Leukaemia Remissions, Malignant Blood Disorder +8

Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results

Stephen Bagley, Meghan Logun, Joseph A. Fraietta et al. · Nature Medicine · 2024 · 281 citations

Cancer Immunosurveillance, Glioma, Immunology +9

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma

Alfred L. Garfall, Edward A. Stadtmauer, Wei‐Ting Hwang et al. · JCI Insight · 2018 · 193 citations · Full text